NOX to Present Clinical Data at COSA Annual Meeting Clinical Oncology Society of AustraliaProvides updates on CEP-1 and DARRT-1 clinical studiesConfirms tolerability of Veyonda®Evidence of durable halt of tumour progression in both studies SYDNEY,...

Noxopharm Releases Report on Key Progress of Subsidiary Nyrada Important progress reported across the Nyrada  therapeutic pipelinePotential first-in-class drugs in development for multiple large underserved indications, including cardiovascular disease, stroke...